JP2024516972A5 - - Google Patents
Info
- Publication number
- JP2024516972A5 JP2024516972A5 JP2023565207A JP2023565207A JP2024516972A5 JP 2024516972 A5 JP2024516972 A5 JP 2024516972A5 JP 2023565207 A JP2023565207 A JP 2023565207A JP 2023565207 A JP2023565207 A JP 2023565207A JP 2024516972 A5 JP2024516972 A5 JP 2024516972A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cancer
- treatment agent
- inhibitor
- tumor treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178922P | 2021-04-23 | 2021-04-23 | |
| US63/178,922 | 2021-04-23 | ||
| PCT/US2022/025875 WO2022226261A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of cancer with a raf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516972A JP2024516972A (ja) | 2024-04-18 |
| JP2024516972A5 true JP2024516972A5 (enExample) | 2025-04-25 |
Family
ID=83722622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565207A Pending JP2024516972A (ja) | 2021-04-23 | 2022-04-22 | Ｒａｆ阻害薬による癌の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11918587B2 (enExample) |
| EP (1) | EP4326256A4 (enExample) |
| JP (1) | JP2024516972A (enExample) |
| KR (1) | KR20240000534A (enExample) |
| CN (1) | CN117561057A (enExample) |
| AU (1) | AU2022261117A1 (enExample) |
| BR (1) | BR112023021913A2 (enExample) |
| CA (1) | CA3216104A1 (enExample) |
| IL (1) | IL307908A (enExample) |
| MX (1) | MX2023012515A (enExample) |
| TW (1) | TW202308645A (enExample) |
| WO (1) | WO2022226261A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024322235A1 (en) * | 2023-08-09 | 2026-02-26 | Pierre Fabre Medicament | Treatment of cancer with a raf inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025145207A1 (en) * | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EA018551B1 (ru) | 2008-02-22 | 2013-08-30 | Айрм Ллк | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| SI3366293T1 (sl) | 2012-06-07 | 2020-08-31 | Deciphera Pharmaceuticals, Llc | Dihidronafthiridini in sorodne spojine uporabne kot kinazni inhibitorji za zdravljenje proliferativnih bolezni |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN107074828B (zh) | 2014-09-12 | 2020-05-19 | 诺华股份有限公司 | 用作raf激酶抑制剂的化合物和组合物 |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| WO2020198058A1 (en) | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| TW202106684A (zh) * | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7626910B2 (ja) * | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) * | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| EP4326255A4 (en) | 2021-04-23 | 2025-03-12 | Pierre Fabre Medicament | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
-
2022
- 2022-04-22 BR BR112023021913A patent/BR112023021913A2/pt unknown
- 2022-04-22 TW TW111115522A patent/TW202308645A/zh unknown
- 2022-04-22 KR KR1020237039412A patent/KR20240000534A/ko active Pending
- 2022-04-22 CA CA3216104A patent/CA3216104A1/en active Pending
- 2022-04-22 MX MX2023012515A patent/MX2023012515A/es unknown
- 2022-04-22 WO PCT/US2022/025875 patent/WO2022226261A1/en not_active Ceased
- 2022-04-22 EP EP22792545.0A patent/EP4326256A4/en active Pending
- 2022-04-22 JP JP2023565207A patent/JP2024516972A/ja active Pending
- 2022-04-22 IL IL307908A patent/IL307908A/en unknown
- 2022-04-22 CN CN202280045318.4A patent/CN117561057A/zh active Pending
- 2022-04-22 AU AU2022261117A patent/AU2022261117A1/en active Pending
-
2023
- 2023-04-06 US US18/296,726 patent/US11918587B2/en active Active
-
2024
- 2024-01-26 US US18/424,274 patent/US12569496B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516972A5 (enExample) | ||
| Meadows et al. | Anti-VEGF therapies in the clinic | |
| Atreya et al. | Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches | |
| JP5563950B2 (ja) | 組合せ療法 | |
| JP2020105162A5 (enExample) | ||
| JP2024526145A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤を含む組合せ医薬及び癌の治療のためのその使用 | |
| De Bono et al. | Therapeutics targeting signal transduction for patients with colorectal carcinoma | |
| JP2020533298A (ja) | Ｈｅｒ誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法 | |
| AU2009210656A1 (en) | Use of picoplatin and cetuximab to treat colorectal cancer | |
| US11384142B2 (en) | Combination therapy for the treatment of ovarian cancer | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| Argiris et al. | Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer | |
| CA2902144C (en) | Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| US20250255857A1 (en) | Methods of treating androgen receptor-independent prostate cancer | |
| Pfeiffer et al. | Current role of antibody therapy in patients with metastatic colorectal cancer | |
| CA2495487A1 (en) | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| RU2619335C2 (ru) | Тетрагидрофолаты в комбинации с ингибиторами egfr | |
| AU2020278733B2 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| Bellmunt | Current treatment in advanced renal cell carcinoma (RCC): impact of targeted therapies in the management of RCC | |
| Jimeno et al. | Membrane receptor and antiangiogenic targeted therapies in the treatment of cancer | |
| Lopez | EORTC-NCI-AACR-30th International Symposium-Molecular Targets and Cancer Therapeutics. Dublin, Ireland-November 13-16, 2018 | |
| Cole | Capmatinib. HGFR (MET; c-Met) inhibitor, Antitumor agent | |
| US20160367553A1 (en) | Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate |